SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-05-1495. This Article Full Text (PDF) All Versions of this Article: 2003-05-1495v1 103/2/442    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cave, H. Articles by Dastugue, N. Search for Related Content PubMed PubMed Citation Articles by Cave, H. Articles by Dastugue, N. Social Bookmarking                   What's this? Submitted May 12, 2003 Accepted August 28, 2003 Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951 Helene Cave*, Stefan Suciu, Claude Preudhomme, Bruce Poppe, Alain Robert, Anne Uyttebroeck, Michele Malet, Patrick Boutard, Yves Benoit, Laurent Mauvieux, Patrick Lutz, Francoise Mechninaud, Nathalie Grardel, Francoise Mazingue, Madeleine Dupont, Genevieve Margueritte, Marie-Pierre Pages, Yves Bertrand, Emmanuel Plouvier, Ghislaine Brunie, Christian Bastard, Dominique Plantaz, Isabel Vande Velde, Anne Hagemeijer, Frank Speleman, Michel Lessard, Jacques Otten, Etienne Vilmer, and Nicole Dastugue Laboratoire de Biochimie Genetique, Hopital Robert Debre (AP-HP), Paris, France; Unite 417, INSERM, Paris, France Data Center, EORTC, Brussels, Belgium Laboratoire d'Hematologie A, Hopital Calmette, Lille, France Universitair Ziekenhuis Ghent, Ghent, Belgium Unite d'Hematologie Infantile, Hopital Purpan, Toulouse, France U.Z Gasthuisberg, Leuven, Belgium Unite d'Onco-Hematologie Pediatrique, CHU, Caen, France Hopital universitaire Hautepierre, Strasbourg, France CHR Hotel Dieu, Nantes, France CHR de Lille, Lille, France Hopital Arnaud de Villeneuve, Montpellier, France Hopital Debrousse, Lyon, France CHR de Besancon - Hopital Saint Jacques, Besancon, France Centre Henri Becquerel, Rouen, France CHU de Grenoble, La Tronche, France Akademisch Ziekenhuis-VUB, Brussels, Belgium Service d'Immuno-Hematologie Pediatrique, Hopital Robert Debre (AP-HP), Paris, France Laboratoire d'Hematologie, Hopital Purpan, Toulouse, France * Corresponding author; email: cave{at}infobiogen.fr. In a series of 153 children with T-cell malignancies enrolled in 2 consecutive EORTC trials, we assessed the HOX11L2 expression and/or the presence of a t(5;14)(q35;q32). Additionally, in 138 of these patients, HOX11 expression and SIL-TAL rearrangement were also assessed. These alterations were mutually exclusive and their frequency was 23% (n=35), 7% (n=10) and 12% (n=17) respectively. HOX11L2/t(5;14) positivity was more frequent in ALL with cortical T- immunophenotype and in children between 6 and 9 years of age. In contrast with previously reported data, HOX11L2/t(5;14) positive and negative patients were comparable with regard to clinical outcome as well as to the response to a 7-day prephase treatment or to residual disease at completion of induction therapy. The 3-year event-free survival (EFS) rate (±SE%) for HOX11L2/t(5;14) positive and negative patients was 75.5% (±8.1%) and 68.3% (±5.0%) respectively; the hazard ratio was 0.84 [95% confidence interval (0.40, 1.80)]. Patients with HOX11-high expression and those with SIL-TAL fusion had low levels of residual disease at the end of induction and a favorable prognosis: the 3-year EFS rate was 83.3% (±8.5%) and 75.3% (±12.6%) respectively. The results obtained in HOX11L2/t(5;14) patients in this study do not confirm the unfavorable prognosis reported in previous studies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P. Ballerini, J. Landman-Parker, J. M. Cayuela, V. Asnafi, M. Labopin, V. Gandemer, Y. Perel, G. Michel, T. Leblanc, C. Schmitt, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome Haematologica, November 1, 2008; 93(11): 1658 - 1665. [Abstract] [Full Text] [PDF] F. Baleydier, A.-V. Decouvelaere, J. Bergeron, P. Gaulard, D. Canioni, Y. Bertrand, S. Lepretre, B. Petit, H. Dombret, K. Beldjord, et al. T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome Clin. Cancer Res., February 1, 2008; 14(3): 692 - 700. [Abstract] [Full Text] [PDF] J. Bergeron, E. Clappier, I. Radford, A. Buzyn, C. Millien, G. Soler, P. Ballerini, X. Thomas, J. Soulier, H. Dombret, et al. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs Blood, October 1, 2007; 110(7): 2324 - 2330. [Abstract] [Full Text] [PDF] X.-Y. Su, V. Della-Valle, I. Andre-Schmutz, C. Lemercier, I. Radford-Weiss, P. Ballerini, M. Lessard, M. Lafage-Pochitaloff, F. Mugneret, R. Berger, et al. HOX11L2/TLX3 is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32) Blood, December 15, 2006; 108(13): 4198 - 4201. [Abstract] [Full Text] [PDF] C. D. Baldus, T. Burmeister, P. Martus, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, and W. K. Hofmann High Expression of the ETS Transcription Factor ERG Predicts Adverse Outcome in Acute T-Lymphoblastic Leukemia in Adults J. Clin. Oncol., October 10, 2006; 24(29): 4714 - 4720. [Abstract] [Full Text] [PDF] S. Borghini, M. Vargiolu, M. Di Duca, R. Ravazzolo, and I. Ceccherini Nuclear Factor Y Drives Basal Transcription of the Human TLX3, a Gene Overexpressed in T-Cell Acute Lymphocytic Leukemia Mol. Cancer Res., September 1, 2006; 4(9): 635 - 643. [Abstract] [Full Text] [PDF] Y.-M. Zhu, W.-L. Zhao, J.-F. Fu, J.-Y. Shi, Q. Pan, J. Hu, X.-D. Gao, B. Chen, J.-M. Li, S.-M. Xiong, et al. NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis. Clin. Cancer Res., May 15, 2006; 12(10): 3043 - 3049. [Abstract] [Full Text] [PDF] H. Peyriere, E. Jeziorsky, A. Jalabert, M. Cociglio, A. Benketira, J.-P. Blayac, S. Hansel, G. Margueritte, and D. Hillaire-Buys Neurotoxicity Related to Valganciclovir in a Child with Impaired Renal Function: Usefulness of Therapeutic Drug Monitoring Ann. Pharmacother., January 1, 2006; 40(1): 143 - 146. [Abstract] [Full Text] [PDF] S. A. Armstrong and A. T. Look Molecular Genetics of Acute Lymphoblastic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6306 - 6315. [Abstract] [Full Text] [PDF] V. Asnafi, A. Buzyn, X. Thomas, F. Huguet, N. Vey, J.-M. Boiron, O. Reman, J.-M. Cayuela, V. Lheritier, J.-P. Vernant, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study Blood, April 15, 2005; 105(8): 3072 - 3078. [Abstract] [Full Text] [PDF] V. Asnafi, K. Beldjord, M. Libura, P. Villarese, C. Millien, P. Ballerini, E. Kuhlein, M. Lafage-Pochitaloff, E. Delabesse, O. Bernard, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy Blood, December 15, 2004; 104(13): 4173 - 4180. [Abstract] [Full Text] [PDF] C.-H. Pui, M. V. Relling, and J. R. Downing Acute Lymphoblastic Leukemia N. Engl. J. Med., April 8, 2004; 350(15): 1535 - 1548. [Full Text] [PDF] C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer Childhood and Adolescent Lymphoid and Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 118 - 145. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020